BI/Lilly's Jardiance Takes On AstraZeneca's Farxiga With Heart Failure Approval
Blockbuster Gets EU Green Light For HFrEF
Executive Summary
Cardiologists in Europe who have so far been unwilling to embrace the SGLT2 class now have two drugs approved for heart failure with reduced ejection fraction, with Jardiance soon to join Farxiga on the market, potentially attractive options especially for their diabetic patients.
You may also be interested in...
As Entresto Sales Soar, Novartis Braces For Generics Battle
Novartis CEO Vas Narasimhan has told Scrip that the company is “aggressively defending each group of patents” on its cardiovascular blockbuster which topped the $900m sales mark in the fourth quarter.
BI And Lilly Eye Acute Heart Failure Opportunity For Jardiance
Having strongly made the case for Jardiance as a treatment for chronic heart failure, Boehringer Ingelheim and Eli Lilly believe the SGLT2 inhibitor could have a lot of potential in acute heart failure as well after promising data from the EMPULSE study.
Empire Building: Jardiance To Take ‘Special Place’ In Heart Failure
Boehringer Ingelheim’s cardiometabolism head Mohamed Eid considers the impact of EMPEROR-Preserved study on the heart failure treatment landscape and looks ahead at potential new conquests in kidney disease for its SGLT2 inhibitor.